Esophageal and Gastric Cancer, Non-small cell lung cancer (NSCLC)
Follow-Up Treatment (Metastatic Disease)
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types whichexpress carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it istherefore designed as a matrix study. This study aims to assess the antitumor activity,tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combinationtreatments in adult participants with locally advanced/metastatic CEACAM5 expressingtumors. There will be 3 substudies under this Master Protocol that may be conducted inparallel. - PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Gastric Cancer (Substudy GC); - PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC); - PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Part
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types whichexpress carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it istherefore designed as a matrix study. This study aims to assess the antitumor activity,tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combinationtreatments in adult participants with locally advanced/metastatic CEACAM5 expressingtumors. There will be 3 substudies under this Master Protocol that may be conducted inparallel. - PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Gastric Cancer (Substudy GC); - PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC); - PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Part
